Cargando…
The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials
Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects women of childbearing age, resulting in reproductive dysfunction, hyperinsulinemia, and obesity. While several drugs are currently approved for use in these patients, their relative effectiveness remains controversial. The purpos...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354168/ https://www.ncbi.nlm.nih.gov/pubmed/37002532 http://dx.doi.org/10.1007/s43032-023-01222-y |
_version_ | 1785074871524392960 |
---|---|
author | Ye, Zheng-Rong Yan, Can-Qun Liao, Nianchun Wen, Si-Hua |
author_facet | Ye, Zheng-Rong Yan, Can-Qun Liao, Nianchun Wen, Si-Hua |
author_sort | Ye, Zheng-Rong |
collection | PubMed |
description | Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects women of childbearing age, resulting in reproductive dysfunction, hyperinsulinemia, and obesity. While several drugs are currently approved for use in these patients, their relative effectiveness remains controversial. The purpose of this meta-analysis was to evaluate the reproductive efficacy and safety of exenatide, a glucagon-like peptide-1 receptor agonist, versus metformin, an insulin sensitizer, in the treatment of patients with PCOS. Nine randomized controlled trials (RCTs) were included, comprising 785 PCOS patients, of whom 385 received exenatide and 400 received metformin. Compared with metformin, exenatide was significantly more effective in treating these patients, as demonstrated by increased pregnancy rate (relative risk (RR) = 1.93, 95% confidence interval (CI) 1.28 to 2.92, P = 0.002), greater ovulation rate (RR = 1.41, 95% CI 1.11 to 1.80, P = 0.004), decreased body mass index (mean difference = − 1.72 kg/m(2), 95% CI − 2.27 to − 1.18, P = 0.00001), and improved insulin resistance (standard mean difference = − 0.62, 95% CI − 0.91 to − 0.33, P < 0.0001). There was no significant difference in the occurrence of adverse events (gastrointestinal reactions, hypoglycemia, etc.) between the two therapies. However, given the moderate to high quality and possible bias of the included studies, the available evidence is inconclusive. More high-quality studies are needed to assess the effects of exenatide in order to provide stronger evidence for its use in this patient population. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s43032-023-01222-y. |
format | Online Article Text |
id | pubmed-10354168 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-103541682023-07-20 The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials Ye, Zheng-Rong Yan, Can-Qun Liao, Nianchun Wen, Si-Hua Reprod Sci Review Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects women of childbearing age, resulting in reproductive dysfunction, hyperinsulinemia, and obesity. While several drugs are currently approved for use in these patients, their relative effectiveness remains controversial. The purpose of this meta-analysis was to evaluate the reproductive efficacy and safety of exenatide, a glucagon-like peptide-1 receptor agonist, versus metformin, an insulin sensitizer, in the treatment of patients with PCOS. Nine randomized controlled trials (RCTs) were included, comprising 785 PCOS patients, of whom 385 received exenatide and 400 received metformin. Compared with metformin, exenatide was significantly more effective in treating these patients, as demonstrated by increased pregnancy rate (relative risk (RR) = 1.93, 95% confidence interval (CI) 1.28 to 2.92, P = 0.002), greater ovulation rate (RR = 1.41, 95% CI 1.11 to 1.80, P = 0.004), decreased body mass index (mean difference = − 1.72 kg/m(2), 95% CI − 2.27 to − 1.18, P = 0.00001), and improved insulin resistance (standard mean difference = − 0.62, 95% CI − 0.91 to − 0.33, P < 0.0001). There was no significant difference in the occurrence of adverse events (gastrointestinal reactions, hypoglycemia, etc.) between the two therapies. However, given the moderate to high quality and possible bias of the included studies, the available evidence is inconclusive. More high-quality studies are needed to assess the effects of exenatide in order to provide stronger evidence for its use in this patient population. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s43032-023-01222-y. Springer International Publishing 2023-03-31 /pmc/articles/PMC10354168/ /pubmed/37002532 http://dx.doi.org/10.1007/s43032-023-01222-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Ye, Zheng-Rong Yan, Can-Qun Liao, Nianchun Wen, Si-Hua The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials |
title | The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials |
title_full | The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials |
title_fullStr | The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials |
title_full_unstemmed | The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials |
title_short | The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials |
title_sort | effectiveness and safety of exenatide versus metformin in patients with polycystic ovary syndrome: a meta-analysis of randomized controlled trials |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354168/ https://www.ncbi.nlm.nih.gov/pubmed/37002532 http://dx.doi.org/10.1007/s43032-023-01222-y |
work_keys_str_mv | AT yezhengrong theeffectivenessandsafetyofexenatideversusmetformininpatientswithpolycysticovarysyndromeametaanalysisofrandomizedcontrolledtrials AT yancanqun theeffectivenessandsafetyofexenatideversusmetformininpatientswithpolycysticovarysyndromeametaanalysisofrandomizedcontrolledtrials AT liaonianchun theeffectivenessandsafetyofexenatideversusmetformininpatientswithpolycysticovarysyndromeametaanalysisofrandomizedcontrolledtrials AT wensihua theeffectivenessandsafetyofexenatideversusmetformininpatientswithpolycysticovarysyndromeametaanalysisofrandomizedcontrolledtrials AT yezhengrong effectivenessandsafetyofexenatideversusmetformininpatientswithpolycysticovarysyndromeametaanalysisofrandomizedcontrolledtrials AT yancanqun effectivenessandsafetyofexenatideversusmetformininpatientswithpolycysticovarysyndromeametaanalysisofrandomizedcontrolledtrials AT liaonianchun effectivenessandsafetyofexenatideversusmetformininpatientswithpolycysticovarysyndromeametaanalysisofrandomizedcontrolledtrials AT wensihua effectivenessandsafetyofexenatideversusmetformininpatientswithpolycysticovarysyndromeametaanalysisofrandomizedcontrolledtrials |